A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

INTRODUCTION: Talimogene laherparepvec (T-VEC; IMLYGIC(®), Amgen Inc.) is an oncolytic immunotherapy approved in Europe for the treatment of unresectable metastatic melanoma (stage IIIB–IVM1a). This study characterised real-world use of T-VEC in four European countries. METHODS: Data on demographics...

Descripción completa

Detalles Bibliográficos
Autores principales: van Akkooi, Alexander C. J., Haferkamp, Sebastian, Papa, Sophie, Franke, Viola, Pinter, Andreas, Weishaupt, Carsten, Huber, Margit A., Loquai, Carmen, Richtig, Erika, Gokani, Priya, Öhrling, Katarina, Louie, Karly S., Mohr, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889564/
https://www.ncbi.nlm.nih.gov/pubmed/33368016
http://dx.doi.org/10.1007/s12325-020-01590-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889564/
https://www.ncbi.nlm.nih.gov/pubmed/33368016
http://dx.doi.org/10.1007/s12325-020-01590-w

Ejemplares similares